Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
Identifieur interne : 001591 ( Pmc/Curation ); précédent : 001590; suivant : 001592Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
Auteurs : M. Rabaglio [Suisse] ; Z. Sun [États-Unis] ; K. N. Price [États-Unis] ; M. Castiglione-Gertsch [Suisse] ; H. Hawle [Suisse] ; B. Thürlimann ; H. Mouridsen [Danemark] ; M. Campone [France] ; J. F. Forbes [Australie] ; R. J. Paridaens [Belgique] ; M. Colleoni [Italie] ; T. Pienkowski [Pologne] ; J.-M. Nogaret [Belgique] ; I. Láng [Hongrie] ; I. Smith [Royaume-Uni] ; R. D. Gelber [États-Unis] ; A. Goldhirsch [Italie, Suisse] ; A. S. Coates [Australie]Source :
- Annals of Oncology [ 0923-7534 ] ; 2009.
Abstract
Url:
DOI: 10.1093/annonc/mdp033
PubMed: 19474112
PubMed Central: 2731016
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001731
Links to Exploration step
PMC:2731016Curation
No country items
B. Thürlimann<affiliation><nlm:aff id="aff5">Senology Center of Eastern Switzerland and Swiss Group for Clinical Cancer Research (SAKK), Kantonsspital, St Gallen, Switzerland, Swiss Group for Clinical Cancer Research (SAKK)</nlm:aff><wicri:noCountry code="subfield">Swiss Group for Clinical Cancer Research (SAKK)</wicri:noCountry></affiliation>Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial</title><author><name sortKey="Rabaglio, M" sort="Rabaglio, M" uniqKey="Rabaglio M" first="M." last="Rabaglio">M. Rabaglio</name><affiliation wicri:level="1"><nlm:aff id="aff1">IBCSG Coordinating Center and Inselspital, Bern, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>IBCSG Coordinating Center and Inselspital, Bern</wicri:regionArea></affiliation></author><author><name sortKey="Sun, Z" sort="Sun, Z" uniqKey="Sun Z" first="Z." last="Sun">Z. Sun</name><affiliation wicri:level="2"><nlm:aff id="aff2">IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Price, K N" sort="Price, K N" uniqKey="Price K" first="K. N." last="Price">K. N. Price</name><affiliation wicri:level="1"><nlm:aff id="aff3">IBCSG Statistical Center and Frontier Science and Technology Research Foundation, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>IBCSG Statistical Center and Frontier Science and Technology Research Foundation, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Castiglione Gertsch, M" sort="Castiglione Gertsch, M" uniqKey="Castiglione Gertsch M" first="M." last="Castiglione-Gertsch">M. Castiglione-Gertsch</name><affiliation wicri:level="3"><nlm:aff id="aff4">IBCSG Coordinating Center, Bern</nlm:aff><country>Suisse</country><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName><wicri:orgArea>IBCSG Coordinating Center</wicri:orgArea></affiliation></author><author><name sortKey="Hawle, H" sort="Hawle, H" uniqKey="Hawle H" first="H." last="Hawle">H. Hawle</name><affiliation wicri:level="3"><nlm:aff id="aff4">IBCSG Coordinating Center, Bern</nlm:aff><country>Suisse</country><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName><wicri:orgArea>IBCSG Coordinating Center</wicri:orgArea></affiliation></author><author><name sortKey="Thurlimann, B" sort="Thurlimann, B" uniqKey="Thurlimann B" first="B." last="Thürlimann">B. Thürlimann</name><affiliation><nlm:aff id="aff5">Senology Center of Eastern Switzerland and Swiss Group for Clinical Cancer Research (SAKK), Kantonsspital, St Gallen, Switzerland, Swiss Group for Clinical Cancer Research (SAKK)</nlm:aff><wicri:noCountry code="subfield">Swiss Group for Clinical Cancer Research (SAKK)</wicri:noCountry></affiliation></author><author><name sortKey="Mouridsen, H" sort="Mouridsen, H" uniqKey="Mouridsen H" first="H." last="Mouridsen">H. Mouridsen</name><affiliation wicri:level="1"><nlm:aff id="aff6">Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark</nlm:aff><country xml:lang="fr">Danemark</country><wicri:regionArea>Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen</wicri:regionArea></affiliation></author><author><name sortKey="Campone, M" sort="Campone, M" uniqKey="Campone M" first="M." last="Campone">M. Campone</name><affiliation wicri:level="1"><nlm:aff id="aff7">Institut du Cancer Nantes Atlantique, CLCC René Gauducheau, Saint Herblain, Fédération Nationale des Centres de Lutte Contre le Cancer, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Institut du Cancer Nantes Atlantique, CLCC René Gauducheau, Saint Herblain, Fédération Nationale des Centres de Lutte Contre le Cancer</wicri:regionArea></affiliation></author><author><name sortKey="Forbes, J F" sort="Forbes, J F" uniqKey="Forbes J" first="J. F." last="Forbes">J. F. Forbes</name><affiliation wicri:level="1"><nlm:aff id="aff8">Australian New Zealand Breast Cancer Trials Group, University of Newcastle, Calvary Mater Newcastle, Newcastle, New South Wales, Australia</nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea>Australian New Zealand Breast Cancer Trials Group, University of Newcastle, Calvary Mater Newcastle, Newcastle, New South Wales</wicri:regionArea></affiliation></author><author><name sortKey="Paridaens, R J" sort="Paridaens, R J" uniqKey="Paridaens R" first="R. J." last="Paridaens">R. J. Paridaens</name><affiliation wicri:level="1"><nlm:aff id="aff9">Department of Medical Oncology, University Hospital Gasthuisberg, Catholic University of Leuven, Leuven, Belgium</nlm:aff><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Medical Oncology, University Hospital Gasthuisberg, Catholic University of Leuven, Leuven</wicri:regionArea></affiliation></author><author><name sortKey="Colleoni, M" sort="Colleoni, M" uniqKey="Colleoni M" first="M." last="Colleoni">M. Colleoni</name><affiliation wicri:level="1"><nlm:aff id="aff10">Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan</wicri:regionArea></affiliation></author><author><name sortKey="Pienkowski, T" sort="Pienkowski, T" uniqKey="Pienkowski T" first="T." last="Pienkowski">T. Pienkowski</name><affiliation wicri:level="1"><nlm:aff id="aff11">Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland</nlm:aff><country xml:lang="fr">Pologne</country><wicri:regionArea>Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw</wicri:regionArea></affiliation></author><author><name sortKey="Nogaret, J M" sort="Nogaret, J M" uniqKey="Nogaret J" first="J.-M." last="Nogaret">J.-M. Nogaret</name><affiliation wicri:level="1"><nlm:aff id="aff12">Department of Mammary and Pelvic Surgery, Jules Bordet Institute; Brussels, Belgium</nlm:aff><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Mammary and Pelvic Surgery, Jules Bordet Institute; Brussels</wicri:regionArea></affiliation></author><author><name sortKey="Lang, I" sort="Lang, I" uniqKey="Lang I" first="I." last="Láng">I. Láng</name><affiliation wicri:level="1"><nlm:aff id="aff13">Department of Medical Oncology, National Institute of Oncology, Budapest, Hungary</nlm:aff><country xml:lang="fr">Hongrie</country><wicri:regionArea>Department of Medical Oncology, National Institute of Oncology, Budapest</wicri:regionArea></affiliation></author><author><name sortKey="Smith, I" sort="Smith, I" uniqKey="Smith I" first="I." last="Smith">I. Smith</name><affiliation wicri:level="1"><nlm:aff id="aff14">Breast Unit, The Royal Marsden Hospital, London, UK</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Breast Unit, The Royal Marsden Hospital, London</wicri:regionArea></affiliation></author><author><name sortKey="Gelber, R D" sort="Gelber, R D" uniqKey="Gelber R" first="R. D." last="Gelber">R. D. Gelber</name><affiliation wicri:level="1"><nlm:aff id="aff15">IBCSG Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health and Harvard Medical School, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>IBCSG Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health and Harvard Medical School, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Goldhirsch, A" sort="Goldhirsch, A" uniqKey="Goldhirsch A" first="A." last="Goldhirsch">A. Goldhirsch</name><affiliation wicri:level="1"><nlm:aff id="aff16">Department of Medicine, European Institute of Oncology, Milan, Italy</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medicine, European Institute of Oncology, Milan</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="aff17">Oncology Institute of Southern Switzerland, Bellinzona, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Oncology Institute of Southern Switzerland, Bellinzona</wicri:regionArea></affiliation></author><author><name sortKey="Coates, A S" sort="Coates, A S" uniqKey="Coates A" first="A. S." last="Coates">A. S. Coates</name><affiliation wicri:level="1"><nlm:aff id="aff18">International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia</nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea>International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">19474112</idno><idno type="pmc">2731016</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731016</idno><idno type="RBID">PMC:2731016</idno><idno type="doi">10.1093/annonc/mdp033</idno><date when="2009">2009</date><idno type="wicri:Area/Pmc/Corpus">001731</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001731</idno><idno type="wicri:Area/Pmc/Curation">001591</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001591</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial</title><author><name sortKey="Rabaglio, M" sort="Rabaglio, M" uniqKey="Rabaglio M" first="M." last="Rabaglio">M. Rabaglio</name><affiliation wicri:level="1"><nlm:aff id="aff1">IBCSG Coordinating Center and Inselspital, Bern, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>IBCSG Coordinating Center and Inselspital, Bern</wicri:regionArea></affiliation></author><author><name sortKey="Sun, Z" sort="Sun, Z" uniqKey="Sun Z" first="Z." last="Sun">Z. Sun</name><affiliation wicri:level="2"><nlm:aff id="aff2">IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Price, K N" sort="Price, K N" uniqKey="Price K" first="K. N." last="Price">K. N. Price</name><affiliation wicri:level="1"><nlm:aff id="aff3">IBCSG Statistical Center and Frontier Science and Technology Research Foundation, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>IBCSG Statistical Center and Frontier Science and Technology Research Foundation, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Castiglione Gertsch, M" sort="Castiglione Gertsch, M" uniqKey="Castiglione Gertsch M" first="M." last="Castiglione-Gertsch">M. Castiglione-Gertsch</name><affiliation wicri:level="3"><nlm:aff id="aff4">IBCSG Coordinating Center, Bern</nlm:aff><country>Suisse</country><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName><wicri:orgArea>IBCSG Coordinating Center</wicri:orgArea></affiliation></author><author><name sortKey="Hawle, H" sort="Hawle, H" uniqKey="Hawle H" first="H." last="Hawle">H. Hawle</name><affiliation wicri:level="3"><nlm:aff id="aff4">IBCSG Coordinating Center, Bern</nlm:aff><country>Suisse</country><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName><wicri:orgArea>IBCSG Coordinating Center</wicri:orgArea></affiliation></author><author><name sortKey="Thurlimann, B" sort="Thurlimann, B" uniqKey="Thurlimann B" first="B." last="Thürlimann">B. Thürlimann</name><affiliation><nlm:aff id="aff5">Senology Center of Eastern Switzerland and Swiss Group for Clinical Cancer Research (SAKK), Kantonsspital, St Gallen, Switzerland, Swiss Group for Clinical Cancer Research (SAKK)</nlm:aff><wicri:noCountry code="subfield">Swiss Group for Clinical Cancer Research (SAKK)</wicri:noCountry></affiliation></author><author><name sortKey="Mouridsen, H" sort="Mouridsen, H" uniqKey="Mouridsen H" first="H." last="Mouridsen">H. Mouridsen</name><affiliation wicri:level="1"><nlm:aff id="aff6">Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark</nlm:aff><country xml:lang="fr">Danemark</country><wicri:regionArea>Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen</wicri:regionArea></affiliation></author><author><name sortKey="Campone, M" sort="Campone, M" uniqKey="Campone M" first="M." last="Campone">M. Campone</name><affiliation wicri:level="1"><nlm:aff id="aff7">Institut du Cancer Nantes Atlantique, CLCC René Gauducheau, Saint Herblain, Fédération Nationale des Centres de Lutte Contre le Cancer, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Institut du Cancer Nantes Atlantique, CLCC René Gauducheau, Saint Herblain, Fédération Nationale des Centres de Lutte Contre le Cancer</wicri:regionArea></affiliation></author><author><name sortKey="Forbes, J F" sort="Forbes, J F" uniqKey="Forbes J" first="J. F." last="Forbes">J. F. Forbes</name><affiliation wicri:level="1"><nlm:aff id="aff8">Australian New Zealand Breast Cancer Trials Group, University of Newcastle, Calvary Mater Newcastle, Newcastle, New South Wales, Australia</nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea>Australian New Zealand Breast Cancer Trials Group, University of Newcastle, Calvary Mater Newcastle, Newcastle, New South Wales</wicri:regionArea></affiliation></author><author><name sortKey="Paridaens, R J" sort="Paridaens, R J" uniqKey="Paridaens R" first="R. J." last="Paridaens">R. J. Paridaens</name><affiliation wicri:level="1"><nlm:aff id="aff9">Department of Medical Oncology, University Hospital Gasthuisberg, Catholic University of Leuven, Leuven, Belgium</nlm:aff><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Medical Oncology, University Hospital Gasthuisberg, Catholic University of Leuven, Leuven</wicri:regionArea></affiliation></author><author><name sortKey="Colleoni, M" sort="Colleoni, M" uniqKey="Colleoni M" first="M." last="Colleoni">M. Colleoni</name><affiliation wicri:level="1"><nlm:aff id="aff10">Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan</wicri:regionArea></affiliation></author><author><name sortKey="Pienkowski, T" sort="Pienkowski, T" uniqKey="Pienkowski T" first="T." last="Pienkowski">T. Pienkowski</name><affiliation wicri:level="1"><nlm:aff id="aff11">Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland</nlm:aff><country xml:lang="fr">Pologne</country><wicri:regionArea>Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw</wicri:regionArea></affiliation></author><author><name sortKey="Nogaret, J M" sort="Nogaret, J M" uniqKey="Nogaret J" first="J.-M." last="Nogaret">J.-M. Nogaret</name><affiliation wicri:level="1"><nlm:aff id="aff12">Department of Mammary and Pelvic Surgery, Jules Bordet Institute; Brussels, Belgium</nlm:aff><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Mammary and Pelvic Surgery, Jules Bordet Institute; Brussels</wicri:regionArea></affiliation></author><author><name sortKey="Lang, I" sort="Lang, I" uniqKey="Lang I" first="I." last="Láng">I. Láng</name><affiliation wicri:level="1"><nlm:aff id="aff13">Department of Medical Oncology, National Institute of Oncology, Budapest, Hungary</nlm:aff><country xml:lang="fr">Hongrie</country><wicri:regionArea>Department of Medical Oncology, National Institute of Oncology, Budapest</wicri:regionArea></affiliation></author><author><name sortKey="Smith, I" sort="Smith, I" uniqKey="Smith I" first="I." last="Smith">I. Smith</name><affiliation wicri:level="1"><nlm:aff id="aff14">Breast Unit, The Royal Marsden Hospital, London, UK</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Breast Unit, The Royal Marsden Hospital, London</wicri:regionArea></affiliation></author><author><name sortKey="Gelber, R D" sort="Gelber, R D" uniqKey="Gelber R" first="R. D." last="Gelber">R. D. Gelber</name><affiliation wicri:level="1"><nlm:aff id="aff15">IBCSG Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health and Harvard Medical School, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>IBCSG Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health and Harvard Medical School, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Goldhirsch, A" sort="Goldhirsch, A" uniqKey="Goldhirsch A" first="A." last="Goldhirsch">A. Goldhirsch</name><affiliation wicri:level="1"><nlm:aff id="aff16">Department of Medicine, European Institute of Oncology, Milan, Italy</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medicine, European Institute of Oncology, Milan</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="aff17">Oncology Institute of Southern Switzerland, Bellinzona, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Oncology Institute of Southern Switzerland, Bellinzona</wicri:regionArea></affiliation></author><author><name sortKey="Coates, A S" sort="Coates, A S" uniqKey="Coates A" first="A. S." last="Coates">A. S. Coates</name><affiliation wicri:level="1"><nlm:aff id="aff18">International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia</nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea>International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales</wicri:regionArea></affiliation></author></analytic><series><title level="j">Annals of Oncology</title><idno type="ISSN">0923-7534</idno><idno type="eISSN">1569-8041</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><bold>Background:</bold> To compare the incidence and timing of bone fractures in postmenopausal women treated with 5 years of adjuvant tamoxifen or letrozole for endocrine-responsive early breast cancer in the Breast International Group (BIG) 1-98 trial.</p><p><bold>Methods:</bold> We evaluated 4895 patients allocated to 5 years of letrozole or tamoxifen in the BIG 1-98 trial who received at least some study medication (median follow-up 60.3 months). Bone fracture information (grade, cause, site) was collected every 6 months during trial treatment.</p><p><bold>Results:</bold> The incidence of bone fractures was higher among patients treated with letrozole [228 of 2448 women (9.3%)] versus tamoxifen [160 of 2447 women (6.5%)]. The wrist was the most common site of fracture in both treatment groups. Statistically significant risk factors for bone fractures during treatment included age, smoking history, osteoporosis at baseline, previous bone fracture, and previous hormone replacement therapy.</p><p><bold>Conclusions:</bold> Consistent with other trials comparing aromatase inhibitors to tamoxifen, letrozole was associated with an increase in bone fractures. Benefits of superior disease control associated with letrozole and lower incidence of fracture with tamoxifen should be considered with the risk profile for individual patients.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Oncol</journal-id><journal-id journal-id-type="hwp">annonc</journal-id><journal-id journal-id-type="publisher-id">annonc</journal-id><journal-title-group><journal-title>Annals of Oncology</journal-title></journal-title-group><issn pub-type="ppub">0923-7534</issn><issn pub-type="epub">1569-8041</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19474112</article-id><article-id pub-id-type="pmc">2731016</article-id><article-id pub-id-type="doi">10.1093/annonc/mdp033</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject><subj-group><subject>Breast Cancer</subject></subj-group></subj-group></article-categories><title-group><article-title>Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rabaglio</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Z.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Price</surname><given-names>K. N.</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Castiglione-Gertsch</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hawle</surname><given-names>H.</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Thürlimann</surname><given-names>B.</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Mouridsen</surname><given-names>H.</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Campone</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Forbes</surname><given-names>J. F.</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Paridaens</surname><given-names>R. J.</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Colleoni</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Pienkowski</surname><given-names>T.</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Nogaret</surname><given-names>J.-M.</given-names></name><xref ref-type="aff" rid="aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Láng</surname><given-names>I.</given-names></name><xref ref-type="aff" rid="aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>I.</given-names></name><xref ref-type="aff" rid="aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Gelber</surname><given-names>R. D.</given-names></name><xref ref-type="aff" rid="aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Goldhirsch</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="aff16">16</xref><xref ref-type="aff" rid="aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Coates</surname><given-names>A. S.</given-names></name><xref ref-type="aff" rid="aff18">18</xref></contrib><contrib contrib-type="author"><collab>for the BIG 1-98 Collaborative and International Breast Cancer Study Groups</collab></contrib></contrib-group><aff id="aff1"><label>1</label>IBCSG Coordinating Center and Inselspital, Bern, Switzerland</aff><aff id="aff2"><label>2</label>IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA</aff><aff id="aff3"><label>3</label>IBCSG Statistical Center and Frontier Science and Technology Research Foundation, Boston, MA, USA</aff><aff id="aff4"><label>4</label>IBCSG Coordinating Center, Bern</aff><aff id="aff5"><label>5</label>Senology Center of Eastern Switzerland and Swiss Group for Clinical Cancer Research (SAKK), Kantonsspital, St Gallen, Switzerland, Swiss Group for Clinical Cancer Research (SAKK)</aff><aff id="aff6"><label>6</label>Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark</aff><aff id="aff7"><label>7</label>Institut du Cancer Nantes Atlantique, CLCC René Gauducheau, Saint Herblain, Fédération Nationale des Centres de Lutte Contre le Cancer, France</aff><aff id="aff8"><label>8</label>Australian New Zealand Breast Cancer Trials Group, University of Newcastle, Calvary Mater Newcastle, Newcastle, New South Wales, Australia</aff><aff id="aff9"><label>9</label>Department of Medical Oncology, University Hospital Gasthuisberg, Catholic University of Leuven, Leuven, Belgium</aff><aff id="aff10"><label>10</label>Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy</aff><aff id="aff11"><label>11</label>Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland</aff><aff id="aff12"><label>12</label>Department of Mammary and Pelvic Surgery, Jules Bordet Institute; Brussels, Belgium</aff><aff id="aff13"><label>13</label>Department of Medical Oncology, National Institute of Oncology, Budapest, Hungary</aff><aff id="aff14"><label>14</label>Breast Unit, The Royal Marsden Hospital, London, UK</aff><aff id="aff15"><label>15</label>IBCSG Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health and Harvard Medical School, Boston, MA, USA</aff><aff id="aff16"><label>16</label>Department of Medicine, European Institute of Oncology, Milan, Italy</aff><aff id="aff17"><label>17</label>Oncology Institute of Southern Switzerland, Bellinzona, Switzerland</aff><aff id="aff18"><label>18</label>International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia</aff><author-notes><corresp id="cor1"><label>*</label><italic>Correspondence to:</italic> M. Rabaglio, International Breast Cancer Study Group Coordinating Center, Effingerstrasse 40, CH-3008 Bern, Switzerland; Tel: +41 31 389 93 91; Fax: +41 31 389 93 92; E-mail: <email>manuela.rabaglio@ibcsg.org</email>.</corresp></author-notes><pmc-comment>Fake ppub date generated by PMC from publisher pub-date/@pub-type='epub-ppub' </pmc-comment>
<pub-date pub-type="ppub"><month>9</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>27</day><month>5</month><year>2009</year></pub-date><volume>20</volume><issue>9</issue><fpage>1489</fpage><lpage>1498</lpage><history><date date-type="received"><day>2</day><month>12</month><year>2008</year></date><date date-type="rev-recd"><day>15</day><month>1</month><year>2009</year></date><date date-type="accepted"><day>19</day><month>1</month><year>2009</year></date></history><permissions><copyright-statement>© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org</copyright-statement><copyright-year>2009</copyright-year></permissions><abstract><p><bold>Background:</bold> To compare the incidence and timing of bone fractures in postmenopausal women treated with 5 years of adjuvant tamoxifen or letrozole for endocrine-responsive early breast cancer in the Breast International Group (BIG) 1-98 trial.</p><p><bold>Methods:</bold> We evaluated 4895 patients allocated to 5 years of letrozole or tamoxifen in the BIG 1-98 trial who received at least some study medication (median follow-up 60.3 months). Bone fracture information (grade, cause, site) was collected every 6 months during trial treatment.</p><p><bold>Results:</bold> The incidence of bone fractures was higher among patients treated with letrozole [228 of 2448 women (9.3%)] versus tamoxifen [160 of 2447 women (6.5%)]. The wrist was the most common site of fracture in both treatment groups. Statistically significant risk factors for bone fractures during treatment included age, smoking history, osteoporosis at baseline, previous bone fracture, and previous hormone replacement therapy.</p><p><bold>Conclusions:</bold> Consistent with other trials comparing aromatase inhibitors to tamoxifen, letrozole was associated with an increase in bone fractures. Benefits of superior disease control associated with letrozole and lower incidence of fracture with tamoxifen should be considered with the risk profile for individual patients.</p></abstract><kwd-group><kwd>aromatase inhibitor</kwd><kwd>bone fracture</kwd><kwd>hormonal therapy</kwd><kwd>letrozole</kwd><kwd>tamoxifen</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001591 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 001591 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:2731016
|texte= Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:19474112" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |